GD2-CAR CAR T cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter

Azlann B Arnett; Andras Heczey

doi:10.1016/j.ccell.2023.11.012

GD2-CAR CAR T cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter

Cancer Cell. 2024 Jan 8;42(1):8-10. doi: 10.1016/j.ccell.2023.11.012. Epub 2023 Dec 21.

Authors

Azlann B Arnett¹, Andras Heczey²

Affiliations

¹ Center for Advanced Innate Cell Therapy, Houston, TX, USA.
² Center for Advanced Innate Cell Therapy, Houston, TX, USA; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX, USA. Electronic address: heczey@bcm.edu.

PMID: 38134937
DOI: 10.1016/j.ccell.2023.11.012

Abstract

GD2-CAR T cells were safe and anti-tumor responses were limited. In this issue of Cancer Cell, Kaczanowska et al. find that apheresis products and peripheral blood at baseline contained significantly higher proportions of CXCR3+ monocytes in good expanders. CXCR3+ monocytes may influence CAR T cell function.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Bone Neoplasms*
Humans
Immunotherapy, Adoptive
Neuroblastoma* / pathology
Neuroblastoma* / therapy
Osteosarcoma* / therapy
Receptors, Antigen, T-Cell
T-Lymphocytes / pathology

Substances

Receptors, Antigen, T-Cell